Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma

Figure 6

In vivo assessment of defactinib and dasatinib combination treatment in a DSRCT and ERMS model. (a) Relative tumor volume (RTV) following 28 days of vehicle, defactinib (50 mg/kg/day), dasatinib (50 mg/kg/day), and combination treatment in the JN-DSRCT-1 in vivo model. (b) Relative tumor volume (RTV) following 21 days of vehicle, defactinib (50 mg/kg/day), dasatinib (50 mg/kg/day), and combination treatment in the RD in vivo model. (c–f) The level of viable tumor tissue (HE), caspase-3 (casp-3), pFAK, and pSrc expressions following vehicle, single-agent defactinib, single-agent dasatinib, and combination treatment in vivo in the JN-DSRCT-1 (c-d) and RD (e-f) models. The differences between pFAK and pSrc expression showed similar significance levels (i.e., -value <0.001) in the JN-DSRCT-1 model compared to the RD model. One representative line and asterisks are given. The level of FAK, Src, and ƴH2AX expressions following vehicle, single-agent defactinib, single-agent dasatinib, and combination treatment in vivo in the JN-DSRCT-1 (g) and RD (h) models. The differences between FAK, Src, and ƴH2AX expressions between treatment groups in both models (i). -value <0.05, -value <0.01, and -value <0.001. HE: hematoxylin and eosin staining.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)